JouleX, which has had previous investment from Cisco, has been acquired by the computer network server company for $107m.

Capital18, the corporate venturing unit of India-based Media & Investments (Network18) has been on a very active exit path over the past 12 months, namely with its latest divestment in India-based digital media agency, Webchutney. Capital 18 has sold its 70% stake to the India unit of Japan-based advertising agency, Dentsu, for an undisclosed sum, which has reportedly made investors three times their investment.

Solera Network, the US-based network security analytics provider, sold to Blue Coat Systems.

Morgan Stanley-backed EKOS snapped up for $180m.

Biogen Idec-backed Portola Pharmaceuticals raises $122m on Nasdaq.

SAP and Time Warner-backed video advertising company files for IPO.

Elan is buying AOP Orphan Pharmaceuticals, which has a minority stake in Shield Therapeutics, a Switzerland-based specialty pharmaceutical company.

The deal is WM's first corporate venturing exit and Joe Vaillancourt, vice-president of WM's organic growth group venture investing, by email said: "We actually have four exits underway. It has been a pretty busy year."

Epizyme sold 5.1 million shares at $15 each compared to plans to offer 4.285 million shares at between $13 and $15 each.

Better Place had by then raised a total of $850m in funding. $111m was raised in a Series A in 2007 led by Lend Lease Ventures